A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD–56-positive Multiple Myeloma

  • Sikander Ailawadhi
  • , Kevin R. Kelly
  • , Robert A. Vescio
  • , Sundar Jagannath
  • , Jeffrey Wolf
  • , Mecide Gharibo
  • , Taimur Sher
  • , Leyla Bojanini
  • , Maurice Kirby
  • , Asher Chanan-Khan

Research output: Contribution to journal › Article › peer-review

63 Scopus citations

Fingerprint

Dive into the research topics of 'A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD–56-positive Multiple Myeloma'. Together they form a unique fingerprint.
Sort by

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science